Feb 21, 2022
RNS Number : 2025C MaxCyte, Inc. 21 February 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Consolidation of Trading Lines   Total voting rights       Gaithersburg, Maryland - 21 February 2022:      MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling   platform
Feb 14, 2022
GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Feb 14, 2022
RNS Number : 5088B MaxCyte, Inc. 14 February 2022   MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , February 14, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies
Feb 14, 2022
RNS Number : 5087B MaxCyte, Inc. 14 February 2022   MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , February 14, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
Feb 01, 2022
RNS Number : 2329A MaxCyte, Inc. 01 February 2022                                                                                                         MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs   Intima Bioscience to use
Jan 24, 2022
RNS Number : 3037Z MaxCyte, Inc. 24 January 2022       MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results   ·      Fourth quarter 2021 revenue expected to be greater than $10 million   ·      Full year 2021 revenue expected to be greater than $33.7
Displaying 51 - 59 of 59